Kukushkin M L, Ivanova A F, Ovechkin A M, Gnezdilov A V, Reshetniak V K
Laboratory of Pathophysiology, NII Common Pathology and Pathophysiology RAMN.
Anesteziol Reanimatol. 1996 Jul-Aug(4):39-42.
The authors consider that failures in the treatment of phantom pain syndrome (PPS) are explained by the lack of individual approach to the clinical manifestations of the syndrome. Three main clinical forms of PPS are distinguished using McGillow's questionnaire: causalgic, neuralgic, and spastic. Differentiated therapy for each form is proposed: combinations of amitriptyline, propranolol, and phenazepam for the first form, carbamazepine, propranolol, and phenazepam for the second, and tizanidine monotherapy for the third form. The efficacy of such therapy is approximately 75.2%, incidence of relapses during a year's follow up 12.4%.
